Balcinrenone
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Balcinrenone
- Molecular weight
- 399.38
- Structure (SMILES)
- CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2
- azd 9977
- Azd 9977
- AZD 9977 [WHO-DD]
- azd 9977 who dd
- Azd-9977
- AZD-9977
- azd9977
- Azd9977
- AZD9977
- AZD9977 capsule
- AZD9977 capsule 50 mg
- AZD9977 ER capsule (fastvrate)
- AZD9977 ER capsule (Int. rate)
- AZD9977 immediate release (IR) oral suspension
- AZD9977 oral suspension
- AZD9977 Oral suspension (reference)
- AZD9977, oral suspension
- balcinrenona
- Balcinrenona
- balcinrenone
- Balcinrenone
- balcinrenone [INN]
- BALCINRENONE [USAN]
- Balcinrenone 100mg Capsule
- Balcinrenone 50mg Capsule
And 2 more, listed on the interactive page.
- CAS registry numbers
- 1850385-64-6
- ChEMBL ID
- CHEMBL3916929
- InChIKey
- MBKYLPOPYYLTNW-ZDUSSCGKSA-N
- PubChem compound IDs
- 118599727
- FDA ingredient codes (UNII)
- 6C9UKZ0CYE
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- balcinrenone
- Type
- Synthetic organic
- Drug name stem
- -renone
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Mineralocorticoid receptor
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Median affinity
- 6.4
- Affinity units
- pIC50
- Mechanism
- Mineralocorticoid receptor modulator
- Action type
- MODULATOR
- Target
- Mineralocorticoid receptor
- Protein identifier
- P08235
Open Targets mechanisms
- Mechanism
- Mineralocorticoid receptor modulator
- Action type
- MODULATOR
- Target
- Mineralocorticoid receptor
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Heart Failure
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Kidney Failure, Chronic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0024327
- Subject identifier
- D007676
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004285
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 2
- NCT03682497
- NCT03801967
- NCT03804645
- NCT03843060
- NCT04798222
- NCT04469907
- NCT04686591
- NCT05884866
- NCT06350123
- NCT06388616
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 96.97
- Calculated partition coefficient (ALogP)
- 1.7
- Calculated partition coefficient (XLogP)
- 1.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 29
- Molecular formula
- C20H18FN3O5
- Monoisotopic mass
- 399.12304885
- Natural product
- No
- Recorded assays
- 25
- Active assays
- 8
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (165)
- A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers
- A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration
- A Clinical Study Assessing the Effects of a Marketed Dentifrice on Tooth Sensitivity While Undergoing Tooth Bleaching
- A Clinical Study to Assess an Experimental Dentifrice in an Experimental Model of Early Stage Caries
- A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers
- A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects
- A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers
- A Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adults
- A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers
- A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
- A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers
- A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
- A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
- A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
- A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects
- A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects
- A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
- A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching
In development for (6)
- Cardiovascular disorder Phase 1
- Chronic kidney disease Phase 2
- Chronic renal failure syndrome Phase 2
- Heart failure Phase 1
- Kidney disorder Phase 1
- Liver disorder Phase 1
Targets (1)
- NR3C2 Mineralocorticoid receptor modulator